A new therapeutic approach in very refractory diffuse large B-cell lymphoma
ConclusionLow doses of cytotoxic agents for continuous, prolonged periods, with minimal drug-free intervals, represent a novel, active, and easily tolerated approach to management of patients with DLBCL in a terminal phase and improved outcome.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants